Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans-Reference-Cited by-同舟云学术

Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans

Published:2007-01 Issue:1 Volume:51 Page:383-385
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Schwarz Patrick¹,Janbon Guilhem¹,Dromer Françoise¹,Lortholary Olivier¹²,Dannaoui Eric¹³

Affiliation:

1. Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, (CNRS FRE2849), Institut Pasteur, 75724 Paris Cedex 15, France

2. Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Necker-Enfants-Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, 75743 Paris Cedex 15, France

3. Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie—Mycologie, 75015 Paris, France

Abstract

ABSTRACT The combination of flucytosine and amphotericin B was tested against 10 flucytosine-resistant isolates of Cryptococcus neoformans by checkerboard, killing curves, and Etest. Although differences were observed depending on the technique used, antagonism was never observed. The synergistic interaction was related to the mechanism of flucytosine resistance of the isolates.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00446-06

Reference29 articles.

1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

2. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med.301:126-131.

3. 5-Fluorocytosine Resistance in Cryptococcus neoformans

4. Variables Influencing Susceptibility Testing ofCryptococcus neoformansto 5-Fluorocytosine

5. Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis;PLOS ONE;2024-08-01

2. Comparison of the antifungal activity of the pyrimidine analogs flucytosine and carmofur against human-pathogenic dematiaceous fungi;Medical Mycology;2024-03-26

3. Clinical treatment of cryptococcal meningitis: an evidence-based review on the emerging clinical data;Journal of Neurology;2024-01-30

4. 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Substudy of the EnACT Trial Testing Oral Amphotericin;Open Forum Infectious Diseases;2023-11-29

5. A One Health approach to overcoming fungal disease and antifungal resistance;WIREs Mechanisms of Disease;2023-04-26